Ligand-functionalized core–shell nanoparticles for precision therapy of luminal A breast cancer: Emerging strategies, clinical challenges, and future perspectives

Puntos clave

• Core-shell nanoparticles significantly improve targeted drug delivery in luminal A breast cancer therapy, enhancing treatment efficacy.
• Key challenge involves optimizing ligands for better targeting, which can impact clinical outcomes and patient responses.
• Analysis of existing strategies reveals the need for precision therapy to address the unique characteristics of luminal A breast cancer.
• Future perspectives call for integrating novel nanoparticles into therapeutic protocols, emphasizing the importance of clinical validation.